Skip to content
Clinical Trials – home

Johannes Kepler University

Verified siteinfo

Austria Med Campus III, Krankenhausstrasse 9, 4020 Linz, Austria

  • 48 trials recruiting
  • Idiopathic pulmonary fibrosis · Colitis ulcerative · Crohn's disease
  • Adults and children

About Specializations

Johannes Kepler University in Linz, Austria specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Colitis ulcerative, Crohn's disease, Diffuse large B-cell lymphoma, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases Research

At Johannes Kepler University in Linz, the Department of Surgery Division of Cardiac Surgery is involved in studies focused on cardiovascular diseases, especially coronary artery disease. The trials are designed to assess whether new treatment strategies can improve heart-related outcomes and reduce complications after surgery.

  • Evaluating a treatment approach for patients undergoing coronary artery bypass grafting
  • Studying ways to lower the risk of ischemic events and graft failure
  • Comparing the effectiveness of different antiplatelet strategies

These investigations aim to improve recovery, long-term protection, and overall treatment effectiveness in people with serious heart disease.

Neoplasms Research

The site is also contributing to clinical research in neoplasms, with a strong focus on melanoma and Ewing sarcoma. The goal of this work is to test new cancer treatment strategies and improve survival outcomes for patients with advanced or high-risk disease.

  • Testing a new therapy approach for previously treated advanced melanoma
  • Exploring treatment optimization in Ewing sarcoma
  • Assessing whether therapy combinations can improve overall survival and event-free survival

These studies reflect an active effort to refine cancer care and identify more effective options for difficult-to-treat tumors.

Hormonal Diseases Research

Clinical trials in hormonal diseases at this educational institution include research on growth hormone deficiency. The main purpose is to better understand treatment effects on growth outcomes and how closely patients can reach their expected adult height.

  • Studying growth hormone deficiency in children and adolescents
  • Comparing growth-related outcomes between treatment groups
  • Evaluating whether therapy can improve final height results

This research helps clarify the impact of treatment on growth and supports more personalized care for patients with endocrine disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Med Campus III, Krankenhausstrasse 94020 LinzAustria
Recruiting now
48 trials
Conditions studied
76
Partner status
Verified site

More sites in LinzAustria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

79 clinical trials

Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Recruiting

Study on the Long-term Safety of TAK-861 for Patients with Narcolepsy Type 1

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.